Summa Equity Acquires Sengenics to Advance Precision Medicine Through Proteomics

Summa Equity, the purpose-driven private equity firm that invests to solve global challenges, has acquired a majority stake in Sengenics, a functional proteomics company with a proprietary technology called KREX that enables researchers to vastly improve the understanding of the human proteome and immune system. Proteomics, i.e. the large-scale study of proteins, is one of the most important areas for gaining insights into human biology and disease, as protein expressions, structures and functions are critical in reflecting states of health.

Sengenics was first founded in 2008 and went on to commercialise the KREX technology that was originally developed from a joint collaboration between the University of Cambridge and the University of Oxford. The company’s patented KREX technology enables researchers to address both the function and folding structure of proteins using one technology that allows for large numbers of proteins to be studied simultaneously, with high sensitivity and specificity. The combination

Read More

Joonghun Pharmaceutical acquires European CE mark for 6 of its Hyaluronic Acid Dermal Fillers, Lorient

Joonghun

Joonghun
Joonghun
Joonghun

SEOUL, South Korea, Sept. 29, 2020 (GLOBE NEWSWIRE) — A total of 6 products from the Lorient product line of cross-linked hyaluronic acid dermal fillers developed by Joonghun Pharmaceutical (CEO Sukjoon Yoon) have received the CE mark.

Lorient is a premium cross-linked hyaluronic dermal filler that has established a foothold for entry into the European beauty market by proving the safety and quality suitable for global standards through the acquisition of this European certification.

Lorient is intended to be injected into the subcutaneous layer of the skin to temporarily improve facial wrinkles in adults. Hyaluronic acid is a bio-friendly component that is present in the human skin, skeleton and synovial fluid and has qualities of lubrication and moisturizing.

Sukjoon Yoon, CEO of Joonghun Pharmaceutical has said “We wanted to make dermal fillers like the medicines that we make, through strict production management beyond the minimum requirements for

Read More